#cyad

StockTitan

@stocktitan.net

3 months ago

Celyad Oncology: Publication of a Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007) Celyad Oncology SA today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market, that it received a notification of transparency dated November 20, 2025, indicating that CFIP CLYD Limited, an affiliate of Fortress...

#CYAD Celyad Oncology: Publication of a Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

www.stocktitan.net/news/CYAD/celyad-oncolog...

Today’s Beauty💐

@todaysbeauty.bsky.social

5 months ago

A yellow flower sits at the side of a flowering sago palm

Today’s Beauty
October 9, 2025
#nature #photography #beauty #flowers #palm #Sago #cyad #bloom #bloomscroll #color #PhotographersOfBluesky

StockTitan

@stocktitan.net

5 months ago

€3M Research Facility Sale: Celyad Oncology Extends Cash Runway Through Q3 2026 in Strategic Move Biotech firm Celyad Oncology to divest Mont-Saint-Guibert research facility equipment and furniture for €3M. Deal closure expected Q4 2025, extending cash runway by 3 quarters into Q3 2026.

#CYAD Celyad Oncology Announces Research Facility Divestiture

www.stocktitan.net/news/CYAD/celyad-oncolog...

StockTitan

@stocktitan.net

5 months ago

Celyad Oncology Reports First Half Year 2025 Financial Results Celyad Oncology (Euronext: CYAD) reported its financial results for H1 2025, showing a deteriorating financial position. The company's cash position dropped to €0.8 million as of June 30, 2025, compared to €4.2 million at the end of 2024. The net loss increased to €3.7 million (€0.09 per share) from €3.0 million (€0.07 per share) in H1 2024.R&D expenses increased by €0.6 million to €2.1 million, primarily due to higher IP costs and catheter development expenses. G&A expenses remained stable at €1.7 million. The company projects its current cash position will only fund operations into Q4 2025, indicating potential liquidity concerns.

#CYAD Celyad Oncology Reports First Half Year 2025 Financial Results

www.stocktitan.net/news/CYAD/celyad-oncolog...

StockTitan

@stocktitan.net

6 months ago

34.1M Voting Rights: Fortress Investment's Control of Biotech Celyad Oncology Dips Below Key 60% Threshold Fortress Investment affiliate CFIP CLYD's voting rights in Celyad Oncology decreased to 59.41% following double voting rights activation from 2023 private placement shares.

#CYAD Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

www.stocktitan.net/news/CYAD/celyad-oncolog...

StockTitan

@stocktitan.net

6 months ago

Biotech Shutdown: Celyad Oncology Ends CAR-T Research Program, Pivots to IP Licensing Amid Cash Crunch CAR-T cell therapy developer Celyad Oncology discontinues R&D activities and reduces workforce due to limited cash runway extending to Q4 2025. Company to focus on IP licensing and asset sales.

#CYAD Celyad Oncology Announces Discontinuation of R&D Activities

www.stocktitan.net/news/CYAD/celyad-oncolog...

StockTitan

@stocktitan.net

7 months ago

Fortress Investment Takes Majority Control of Celyad Oncology Through $32.7M Share Acquisition Fortress affiliate CFIP CLYD acquires 3.3M additional shares, reaching 60.96% ownership of Celyad Oncology through August 2025 capital increase. See ownership details.

#CYAD Celyad Oncology SA: Publication of a Transparency Notification Received from Fortress Investment Group LLC

www.stocktitan.net/news/CYAD/celyad-oncolog...

StockTitan

@stocktitan.net

7 months ago

Celyad Oncology Just Secured €1M Investment as Fortress Set to Control 58.5% Stake Strategic €1M private placement extends Celyad's runway into Q4 2025. Fortress to become majority shareholder. Get full details on this crucial financing round.

#CYAD Celyad Oncology Announces €1 Million Private Placement

www.stocktitan.net/news/CYAD/celyad-oncolog...

StockTitan

@stocktitan.net

8 months ago

Celyad Oncology Announces Strategic Review Celyad Oncology (NASDAQ:CYAD) has announced a comprehensive strategic review amid financial challenges. The company reported a treasury position of €4.2 million as of December 31, 2024, with cash runway only extending into Q3 2025. The review encompasses potential asset sales, restructuring, mergers, and financing options.The company has already implemented cost-reduction measures, with R&D expenses decreasing to €3.2 million in 2024 (from €4.6 million in 2023) and G&A expenses reducing to €3.2 million (from €6.0 million in 2023). Celyad is currently in discussions for potential out-licensing deals on its CAR-T and shRNA platforms.

#CYAD Celyad Oncology Announces Strategic Review

www.stocktitan.net/news/CYAD/celyad-oncolog...

StockTitan

@stocktitan.net

11 months ago

Celyad Oncology Reports Full Year 2024 Financial Results and Recent Business Highlights Celyad Oncology has reported its full year 2024 financial results, showing a net loss of €5.8 million (€0.14 per share), improved from €8.5 million loss in 2023. The company's treasury position stands at €4.2 million as of December 31, 2024.Key operational highlights include advancement of their multiplex miRNA-based shRNA non-gene editing technology to a 5-plex system and development of multispecific NKG2D-based CAR T-cell platform. The company has also re-initiated manufacturing of C-Cath®, an intra-myocardial injection catheter.Financial metrics show reduced R&D expenses at €3.2 million (down from €4.6 million in 2023) and G&A expenses at €3.2 million (down from €6.0 million). Net cash used in operations decreased significantly to €2.8 million from €15.2 million in 2023. The company projects its current cash position will fund operations into Q3 2025.

#CYAD Celyad Oncology Reports Full Year 2024 Financial Results and Recent Business Highlights

www.stocktitan.net/news/CYAD/celyad-oncolog...

Blanca López (Nuclear Wolf)

@nuclearwolf.bsky.social

1 year ago

Fran presentación con gente chida. Además de los autores, muchas gracias a quienes no salen en la foto pero que hicieron esto posible Sandra Molina, Silvia Arenas, Mary Ángeles, Saúl Vargas, Morgan Rdz y al Departamento de Investigación y Conocimiento
#culturaludica #cyad #SoyUAM #UAMAzcapotzalco

StockTitan

@stocktitan.net

1 year ago

Groundbreaking Cancer Treatment Success: Celyad's New CAR T-Cell Therapy Shows Zero GvHD Cases in Multiple Myeloma Trial Revolutionary miRNA-based therapy demonstrates safety and efficacy in multiple myeloma patients, with no GvHD complications reported in Phase I trials.

#CYAD Celyad Oncology announces the publication of the preclinical and clinical data of CYAD-211 providing proof-of-concept of its miRNA-based shRNA platform

www.stocktitan.net/news/CYAD/celyad-oncolog...